BlueCross BlueShield of Tennessee Medical Policy Manual

Cardiovascular System

• Angioplasty or Stenting for Intracranial Arterial Disease (Atherosclerosis and Aneurysms)

• Baroreflex Stimulation Devices

• Bioimpedance Devices for Detection of Lymphedema

• Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting

• Chelation Therapy

• Computerized 2-lead Resting Electrocardiogram Analysis for the Diagnosis of Coronary Artery Disease

• Coronary Computed Tomography Angiography (CCTA)

• End Diastolic Pneumatic Compression Boot as a Treatment of Peripheral Vascular Disease

• Endovascular Therapies for Extracranial Vertebral Artery Disease

• Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment

• Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or Aneurysm

• Home Apnea Monitoring / Home Cardiorespiratory Monitoring

• Home Spirometry

• KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy

• Myocardial Sympathetic Innervation Imaging for Individuals with Heart Failure

• Positron Emission Tomography (PET) for Cardiac Applications

• Signal Averaged Electrocardiography (SAECG)

• Stem Cell Therapy for Peripheral Artery Disease

• Surgical Ventricular Restoration

• Total Artificial Heart (TAH)

• Ultrasonographic Measurements of Carotid Intima-Medial Thickness (CIMT) as an Assessment of Subclinical Atherosclerosis

• Wearable Cardioverter Defibrillator

This document has been classified as public information.